This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC), specifically in its advanced stages, either stage IV or when it has returned after treatment. The study aims to compare two different treatment approaches to see which one helps patients live longer. One group of participants will receive a combination of two medications, nivolumab and relatlimab, along with chemotherapy. The other group will receive pembrolizumab with chemotherapy. These treatments are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.
The main goal of the study is to determine if the combination of nivolumab and relatlimab with chemotherapy is more effective in extending the lives of patients compared to pembrolizumab with chemotherapy. The study will also look at other factors, such as how long the cancer stays under control and the overall response to the treatments. Participants will be monitored for any side effects from the medications.
The study will take place over several years, with the estimated completion date in 2027. Participants will be randomly assigned to one of the two treatment groups and will receive their assigned treatment as part of the study. The results will help determine the best first-line treatment option for people with this type of lung cancer.
Austria 
Belgium 
Denmark 
France 
Germany 
Ireland 
Italy 
Poland 
Portugal 
Romania 
Spain 
The Netherlands 
